A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants

Lilly

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: [14C]-LY3871801

Study type

Interventional

Funder types

Industry

Identifiers

NCT06049108

J3P-MC-FTAE (Other Identifier)

18337

Details and patient eligibility

About

The main purpose of this study is to evaluate how much of the study drug (LY3871801), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks including the screening period.

Enrollment

8 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male participants who are overtly healthy as determined by medical evaluation
Have a body mass index of 18.5 to 32.0 kilograms per meter squared (kg/m²), inclusive
Males who agree to use highly effective or effective methods of contraception

Exclusion criteria

Have known allergies to LY3871801, related compounds, or any components of the formulation, or a history of significant atopy
Have received or intend to receive any vaccination within 30 days prior to dosing until the follow-up phone call
Have participated in a radiolabeled drug study, where exposures are known to the investigator or designee, within 4 months prior to check-in, or participated in a radiolabeled drug study, where exposures are not known to the investigator or designee, within 6 months prior to check-in